drugset / Trial / NCT05817799

Impact of Hemodialysis on Plasma Carnitine Levels in Patients With End Stage Renal Disease

NCT05817799

Non-randomizedSingle-groupOpen-labelSupportive care

Summary

OBJECTIVES * To assess the levels of plasma carnitine in controls and hemodialysis patients. * To give supplementary L-carnitine to study subjects for a duration of 5months. * To compare the values of plasma carnitine before and after L carnitine supplementation. * To assess the role of carnitine supplementation on biochemical and clinical parameters.

Timeline

Start
2023-01-01
Primary completion
2023-07-02
Completion
2023-07-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject L-carnitine Other / unclassified 20 mg/kg Oral
Subject L-carnitine Other / unclassified 500 mg Oral
Subject L-carnitine Other / unclassified 1 g Oral

Indications

No indication recorded.